Back to mobile site
Get it on Google Play

FDA recommends pre-BLA meeting for Rezolute's congenital HI drug

October 5, 2026 7:00 AM EDT Send to a Friend
Rezolute, Inc. (Nasdaq: RZLT) announced that the U.S. Food and Drug Administration has recommended a pre-biologics license application (BLA) meeting ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login